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The effect of weight, body mass index, age, 
sex, and race on plasma concentrations of 
subcutaneous sumatriptan: a pooled analysis
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Objective/background: Factors such as body size (weight and body mass index [BMI]), age, 
sex, and race might influence the clinical response to sumatriptan. We evaluated the impact 
of these covariates on the plasma concentration (Cp) profile of sumatriptan administered 
subcutaneously.
Methods: We conducted three pharmacokinetic studies of subcutaneous sumatriptan in 98 healthy 
adults. Sumatriptan was administered subcutaneously (236 administrations) as either DFN-11 3 mg, a 
novel 0.5 mL autoinjector being developed by Dr. Reddy’s Laboratories; Imitrex® (Sumatriptan) injec-
tion 3 mg or 6 mg (6 mg/0.5 mL); or Imitrex STATdose 4 mg or 6 mg (0.5 mL). Blood was sampled 
for 12 hours to determine sumatriptan Cp. Maximum Cp (C
max
), area under the curve during the first 
2 hours (AUC
0–2
), and total area under the curve (AUC
0–∞
) were determined using noncompartmental 
methods. Post hoc analyses were conducted to determine the relationship between these exposure 
metrics and each of body weight, BMI, age, sex, and race (categorized as white, black, or others).
Results: Both weight and BMI correlated negatively with each exposure metric for each treat-
ment group. Across all treatment groups, AUC
0–2
 for subjects with BMI less than or equal to 
median value was 1.03–1.12 times the value for subjects with BMI more than median value. 
For subjects with BMI less than or equal to median value receiving DFN-11, median AUC
0–2
 
was slightly less than that for subjects with BMI more than median value receiving Imitrex 
4 mg and larger than that for subjects with BMI more than median value receiving Imitrex 
3 mg. Results were similar for the other exposure metrics and for weight. Exposure was higher 
in women than in men, which can be attributed in part to differences in weight. There was no 
relationship between exposure and age. For DFN-11, AUC
0–2
 and AUC
0–∞
 were lower in non-
whites compared with whites; the ratio of median values was 0.84 and 0.89, respectively. A 
similar, nonstatistically significant, trend was observed in the other products (ratio of median 
values ranging from 0.84 to 0.89).
Conclusion: Weight and BMI appear to be important covariates for sumatriptan exposure: 
subjects with lower values for either metric of body size have higher systemic exposure com-
pared with subjects with higher values. Additional studies are required to determine if doses 
of subcutaneous sumatriptan may be adjusted based on BMI for comparable efficacy and a 
potentially improved tolerability profile.
Keywords: sumatriptan plasma concentration, migraine, body size, BMI, obesity, age, sex, race
Introduction
Migraine is a chronic, disabling neurological disorder with episodic clinical findings 
of headache, often associated with nausea and vomiting. In the US, ~17% of women 
and 6% of men experience migraine.1 Sumatriptan is one of the most commonly used 
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triptans for treatment of migraine attacks. Oral, intranasal 
(IN), and subcutaneous (SC) formulations of sumatriptan are 
approved by the Food and Drug Administration and are mar-
keted in the US and several other countries.2–4 SC sumatriptan 
has a better efficacy profile than oral and IN sumatriptan 
products.2–4 Absorption is more rapid with SC administration 
(time to reach maximum observed [peak] plasma concentra-
tion [t
max
] for SC Imitrex® (Sumatriptan) is 12 minutes [range: 
5–20 minutes]), significantly shorter than that for the oral 
(2–2.5 hours)2–4 and nasal routes (range: 60–90 minutes).5 As 
a result, onset of action with SC sumatriptan (10 minutes) is 
faster than that with IN (30–45 minutes) or oral (45–60 min-
utes) delivery.2–4 There are several published pharmacokinetic 
(PK) studies for sumatriptan; however, few of these examine 
whether sumatriptan PK metrics (ie, C
max
 [maximum plasma 
concentration {Cp}] and AUC [area under the Cp vs time 
curve]) are affected by covariates such as weight, body mass 
index (BMI), age, sex, and race. In addition, sample size for 
many of these studies is small.
Currently, SC sumatriptan is available in 4 mg and 6 mg 
dosage forms (Imitrex STATdose, 0.5 mL) and as an inject-
able solution (Imitrex injection, 6 mg/0.5 mL). A low-dose 
(3 mg) sumatriptan product for SC injection, known as DFN-
11 (ZEMBRACE™SymTouch™, Dr. Reddy’s Laboratories, 
Hyderabad, Telangana, India), is now approved for sale in the 
US. DFN-11 is a single-dose, 0.5 mL prefilled syringe as a 
ready-to-use disposable autoinjector. Efficacy of this 3 mg 
autoinjector is expected to be same as existing sumatriptan 
injection 3 mg products.
We conducted three clinical pharmacology studies 
(unpublished) to support a PK bridge between DFN-11 and 
several Imitrex products; data from these studies were pooled 
as the target populations and study methodologies were 
similar. To understand the impact of covariates on systemic 
exposure of sumatriptan, we examined the relationships 
between sumatriptan PK metric for each product and each 
of weight, BMI, age, sex, and race. Results of this analysis 
could provide insights into treatment outcomes. In addition, 
we evaluated whether subsets of subjects who received DFN-
11 3 mg have systemic exposure comparable to that in subsets 
of subjects who received larger doses of Imitrex.
Methods
We conducted three PK studies of SC sumatriptan in 98 healthy 
adults. The data from three studies were combined for pooled 
data analysis. The protocols were approved by the Chesapeake 
Research Review, Inc., Institutional Review Board, and the 
studies were conducted in compliance with good clinical prac-
tice at Celerion Research (Tempe, AZ and Lincoln, NE). Before 
the studies began, their nature was explained to the subjects, 
and subjects provided written informed consent. All studies 
used a single-dose, open-label, randomized crossover design 
to determine relative bioavailability following SC administra-
tion of sumatriptan succinate in healthy, fasted adults. The 
randomization sequences were generated by Celerion as per 
their Standard Operating Procedure. Each study included DFN-
11 (3 mg/0.5 mL) vs either Imitrex injection (3 mg/0.25 mL 
or 6 mg/0.5 mL) or Imitrex STATdose system (4 mg/0.5 mL 
or 6 mg/0.5 mL). All three studies were conducted from July 
2014 to February 2015. Brief descriptions of the three unpub-
lished studies are as follows: study 001 (DFN-11-CD-001) 
was a two-way crossover study comparing DFN-11 with 
Imitrex injection 3 mg; subjects were randomized to one of 
two treatment sequences. Study 002 (DFN-11-CD-002) was a 
three-way crossover study that compared DFN-11 with Imitrex 
injection 3 mg and 6 mg; subjects were randomized to one of 
six treatment sequences. Study 003 (DFN-11-CD-003) was a 
three-way crossover study comparing DFN-11 with Imitrex 
4 mg STATdose system and 6 mg STATdose system; subjects 
were randomized to one of six treatment sequences. For all 
three studies, in each period, a single dose was administered 
SC over ~5 seconds. PK samples were obtained predose and 
at 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 
1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 
10 hours, and 12 hours postdose. Subjects were confined from 
8 hours before the first dose through the last sample after the 
final dose. Doses were separated by at least 2 days.
Cps of sumatriptan were determined using high-per-
formance liquid chromatography with mass spectrometric 
detection assay, sensitive to 0.5 ng/mL. PK parameters for 
each dosing session were determined using noncompartmen-
tal methods with  WinNonlin Version 6.3 (Certara, St Louis, 
MO, USA) or SAS Version 9.3 (SAS Institute Inc., Cary, NC, 
USA). The following exposure parameters were determined:
1. C
max
: the maximum measured Cp, determined by exami-
nation of the data.
2. AUC
0–2
: area under the Cp vs time curve from the time 
of drug administration to the 2-hour sample.
3. AUC
0–∞
: area under the concentration–time curve from 
the time of drug administration extrapolated to infinity. 
AUC
0–∞
 is calculated as the sum of AUC
0–t
 (where t is the 
last measured nonzero concentration) plus the ratio of 
the last measurable Cp to the elimination rate constant.
AUCs were calculated by the linear trapezoidal method.
Graphics were prepared to examine the relationship 
between each of AUC
0–2
, AUC
0–∞
, and C
max 
and the  following 
covariates: weight (kg), BMI (kg/m2), age (years), sex, and 
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race (categorized as white, black, or other [two subjects listed 
as “multiple” race were characterized as “other”]). For con-
tinuous covariates, the relationship between each metric and 
covariate was evaluated by linear regression  and a smoother 
(Supersmoother, Stanford, CA, USA). In addition, the median 
value for each continuous covariate (weight: 72.2 kg; BMI: 
26.33 kg/m2; and age: 30.5 years) was identified, and the 
median value for the exposure metric for subjects below and 
above that median covariate value was determined; the ratio of 
these values is reported. For example, we compared exposure 
metrics for subjects weighing >72.2 kg with those weighing 
less. For categorical covariates, the mean for each group was 
identified; groups were compared by t-test. The ratio of median 
values for female/male and non-white/white was determined. 
In addition, we conducted multiple regression analyses includ-
ing each of weight or BMI plus either race (Caucasian vs 
non-Caucasian) or sex (race and sex included in the model as 
factors) to determine whether race or sex contributed to dif-
ferences in exposure after accounting for body size.
Safety
Subjects were monitored for injection site reactions including 
pain, tenderness erythema/redness, and induration/swelling 
before dosing and at 6 hours and 12 hours after study drug 
administration in all periods.
Results
Subject disposition
Demographics characteristics are summarized in Table 1. 
All subjects were healthy and none used tobacco. One sub-
ject in Study 001 was found to be pregnant before Period 2 
and was discontinued from the study. In Study 001, an 
incorrect procedure was applied for injection of Imitrex 
3 mg; as a result, data from those sessions were excluded 
from the PK analysis. All remaining sessions were included 
in the PK analyses; all sessions were included in safety 
analyses. Thus, the total number of sessions included in the 
PK analysis was 97 for DFN-11, 35 for Imitrex injection 
3 mg, 36 for Imitrex STATdose 4 mg, and 68 for Imitrex 
STATdose 6 mg. For one session with DFN-11, AUC
0–2
 
could not be determined due to a missing sample at 2 hours; 
however, AUC
0–∞
 could be determined since t
max
 was much 
earlier than 2 hours.
Effect of weight
For each treatment group, increasing weight was associated 
with decreasing sumatriptan exposure (Figures 1–3 and 
Table 2) for all three metrics (P<0.003 [linear regression] 
for each treatment group within each metric). Across all 
treatment groups, AUC
0–2
 for subjects weighing less than 
or equal to median weight was ~1.2 times the value for 
subjects with weight more than median value. For subjects 
with weight less than or equal to median value receiving 
DFN-11, median AUC
0–2
 was similar to that for subjects 
with weight more than median value receiving Imitrex 
4 mg and larger than that for subjects with weight more 
than median value receiving Imitrex 3 mg. AUC
0–∞ 
for 
subjects with weight less than or equal to median value was 
1.12–1.19 times the value for subjects with weight more 
than median value. For subjects  with weight less than or 
equal to median value receiving DFN-11, median AUC
0–∞
 
was slightly less than that for subjects with weight more 
than median value receiving Imitrex 4 mg and markedly 
larger than that for subjects with weight less than or equal 
to median value receiving Imitrex 3 mg. C
max
 for sub-
jects  with weight less than or equal to median value was 
~1.18–1.30 times the value for subjects with weight more 
than median value. For subjects with weight less than or 
equal to median value receiving DFN-11, median C
max
 was 
slightly more than that for subjects with wieght more than 
median value receiving Imitrex 4 mg and markedly larger 
than that for subjects with weight more than median value 
receiving Imitrex 3 mg.
In the multiple regression analyses, after incorporating 
the effect of weight, C
max
 for DFN-11 was 5.8 ng/mL higher 
in women and AUC
0–2
 for DFN-11 was 3.0 ng/mL h higher 
in women (Table 3). After incorporating the effect of weight, 
AUC
0–2
 was 3.3 ng/mL h lower in non-Caucasians with 
DFN-11 and 6.1 ng/mL lower with Imitrex 4 mg. AUC
0–∞ 
was 3.6  ng/mL h lower with DFN-11 and 9.5 ng/mL h lower 
with Imitrex 4 mg (Table 4).
Table 1 Demographic characteristics of the subjects in the three 
studies
Metric Study
001 (N=26) 002 (N=36) 003 (N=36)
Sex (male/
female)
13/13 17/19 16/20
Age (years) 29.1 (21–45) 31.7 (18–45) 32.0 (18–45)
Weight (kg) 78.3 (47.7–113.2) 73.4 (49.3–109.6) 74.8 (51.3–116.5)
Height (cm) 169.9 (151–193) 166.5 (151–184) 166.7 (153–188)
BMI (kg/m2) 27.0 (19.2–34.8) 26.4 (19.6–34.6) 26.7 (19.8–33.8)
Race
White 21 31 31
Black 3 5 2
Other 2 0 4
Note: Values for sex and race are counts; for the other metrics, values are mean 
(range).
Abbreviation: BMI, body mass index.
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Figure 1 Values for Cmax are displayed against weight (top) and BMI (bottom) for each treatment group. 
Notes: Colors indicate study (001: blue; 002: green; and 003: red). A linear regression (green line) and a smoother (Supersmoother, red line) are displayed. Median values for 
all subjects, those with weight less than or equal to median value or BMI, and those with weight or BMI more than median value are displayed. *Generic name: Sumatriptan.
Abbreviations: BMI, body mass index; Cmax, maximum plasma concentration.
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Figure 2 Values for AUC0–2 are displayed against weight (top) and BMI (bottom) for each treatment group.
Notes: Colors indicate study (001: blue; 002: green; and 003: red). A linear regression (green line) and a smoother (Supersmoother, red line) are displayed. Median values for all 
subjects, those with weight less than or equal to median value or BMI, and those with median weight or BMI more than median value are displayed. *Generic name: Sumatriptan. 
Abbreviations: AUC, area under the curve; BMI, body mass index.
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Figure 3 Values for AUC0–∞ are displayed against weight (top) and BMI (bottom) for each treatment group.
Notes: Colors indicate study (001: blue; 002: green; 003: red). A linear regression (green line) and a smoother (Supersmoother, red line) are displayed. Median values for all 
subjects, those with weight less than or equal to median value or BMI, and those with median weight or BMI more than median value are displayed. *Generic name: Sumatriptan. 
Abbreviations: AUC, area under the curve; BMI, body mass index.
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Table 2 Effect of weight on systemic exposure to sumatriptan
Exposure metric DFN-11 3 mg Imitrex‚*
3 mg injection 4 mg STATdose 6 mg STATdose or injection
AUC0–2 (ng/mL h) 45.60/37.28
a 42.21/36.41a 56.61/45.69a 81.96/67.91a
AUC
0–∞
 (ng/mL h) 64.21/53.86a 57.43/50.74a 78.91/67.41a 114.88/102.09a
Cmax (ng/mL) 53.70/41.35
a 49.35/40.50a 62.00/52.85a 93.80/71.20a
Note: Values are (median for subjects with weight less than or equal to median value)/(median for subjects with weight more than median value). aLighter and heaver subjects 
differ (P<0.05) by t-test. *Generic name: Sumatriptan.
Abbreviations: AUC, area under the curve; Cmax, maximum plasma concentration.
Table 3 Additional effect of sex in regression models including weight or BMI (limited to those analyses for which the effect of sex 
was statistically significant)a
Weight/BMI Exposure 
metric
Treatment Intercept Coefficient 
(weight/BMI)
Coefficient (sex) P (weight/BMI)b P (sex)b
Weight Cmax DFN-11, 3 mg 64.407 -0.249 5.827 0.0025 0.0190
Weight AUC0–2 DFN-11, 3 mg 59.253 -0.251 2.966 <0.0001 0.0236
BMI Cmax DFN-11, 3 mg 65.025 -0.786 8.956 0.0015 <0.0001
BMI Cmax Imitrex, 4 mg 65.317 -0.447 8.925 0.3515 0.0134
BMI Cmax Imitrex, 6 mg 150.740 -2.611 14.813 0.0008 0.0093
BMI AUC0–2 DFN-11, 3 mg 54.519 -0.600 6.510 <0.0001 <0.0001
BMI AUC0–2 Imitrex, 3 mg 49.180 -0.443 3.671 0.0503 0.0333
BMI AUC0–2 Imitrex, 4 mg 57.542 -0.377 6.974 0.2488 0.0050
BMI AUC0–2 Imitrex, 6 mg 99.450 -1.051 8.648 0.0050 0.0020
BMI AUC
0–∞
DFN-11, 3 mg 76.903
-0.780 6.113 0.0001 0.0001
BMI AUC
0–∞
Imitrex, 6 mg 139.610
-1.311 8.320 0.0089 0.0242
Note: aExposure was higher in women than men by a ratio of ~1.2:1. bStatistical significance (ANOVA) for inclusion of this term in the model.
Abbreviations: AUC, area under the curve; BMI, body mass index; Cmax, maximum plasma concentration.
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Effect of BMI
For most treatment groups, increasing BMI was associated 
with decreasing sumatriptan exposure (Table 5) for all three 
metrics (P<0.05 [linear regression] for each treatment group 
within each metric); exceptions were AUC
0–∞
 for Imitrex 
3 mg (P=0.052) and C
max
 for Imitrex 4 mg (P=0.061). 
Across all treatment groups, AUC
0–2
 for subjects with BMI 
less than or equal to median value was 1.03–1.12 times 
the value for subjects with BMI more than median value. 
For subjects  with BMI less than or equal to median value 
receiving DFN-11, median AUC
0–2
 was slightly less than 
that for subjects with BMI more than median value receiv-
ing Imitrex 4 mg and larger than that for subjects with BMI 
more than median value receiving Imitrex 3 mg. AUC
0–∞
 
for subjects with BMI less than or equal to  median value 
was 1.03–1.15 times the value for subjects with BMI less 
than or equal to median value. For subjects with BMI less 
than or equal to median value receiving DFN-11, median 
AUC
0–∞
 was less than that for subjects with BMI more than 
median value receiving Imitrex 4 mg and larger than that 
for subjects with BMI more than median value receiving 
Imitrex 3 mg. C
max
 for subjects with BMI less than or equal 
to median value was 1.02–1.14 times the value for subjects 
with BMI more than median value. For subjects with BMI 
less than or equal to  median value receiving DFN-11, 
median C
max
 was less than that for subjects with BMI more 
than median value receiving Imitrex 4 mg and larger than 
that for subjects with BMI more than median value receiv-
ing Imitrex 3 mg.
In the multiple regression analyses, after incorporating 
the effect of BMI, C
max
 was 9.0 ng/mL higher in women 
with DFN-11, 8.9 ng/mL higher with Imitrex 4 mg, and 
14.8 ng/mL higher with Imitrex 6 mg. AUC
0–2
 was 3.7–8.6 ng/
mL h higher in women across the four products. AUC
0–∞
 was 
6.1 ng/mL h higher in women with DFN-11 and 8.3 ng/mL 
h higher with Imitrex 6 mg. After incorporating the effect 
of BMI, C
max
 was 10.9 ng/mL lower in non-Caucasians with 
Imitrex 4 mg, AUC
0–2
 was 5.1–8.7 ng/mL h lower in non-
Caucasians for DFN-11 and Imitrex 4 mg and 6 mg. AUC
0–∞
 
was 5.7–12.3 ng/mL h lower in non-Caucasians for DFN-11 
and Imitrex 4 mg and 6 mg.
Effect of age
There was no relationship between sumatriptan exposure 
and age.
Sex
For most treatment groups, sumatriptan exposure in women 
was higher than in men, the ratio typically being ~1.2. This 
ratio results in part from the difference in weight between 
men and women.
Effect of race
For DFN-11, AUC
0–2
 and AUC
0–∞
 were lower in non-whites 
compared with whites; the ratio of median values was 0.84 
and 0.89, respectively. A similar, nonstatistically significant 
trend was observed in the other products (ratio of median 
values ranging from 0.84 to 0.892).
Safety
In 98 subjects exposed to SC sumatriptan, all reported adverse 
events were among those currently described for marketed 
sumatriptan products. There were no deaths or related seri-
ous adverse events. Only one study (Study 003) included a 
Table 4 Additional effect of race in regression models including weight or BMI (limited to those analyses for which the effect of sex 
was statistically significant)a
Weight/BMI Exposure 
metric
Treatment Intercept Coefficient (weight/BMI) Coefficient (race) P (weight/BMI)b P (race)b
Weight AUC0–2 DFN-11, 3 mg 64.640 -0.295 -3.259 <0.0001 0.0241
Weight AUC0–2 Imitrex, 4 mg 74.769 -0.302 -6.116 0.0001 0.0375
Weight AUC
0–∞
DFN-11, 3 mg 85.113
-0.336 -3.627 <0.0001 0.0661
Weight AUC
0–∞
Imitrex, 4 mg 101.240
-0.360 -9.497 0.0019 0.0381
BMI Cmax Imitrex, 4 mg 90.228 -1.137 -10.925 0.0178 0.0272
BMI AUC0–2 DFN-11, 3 mg 62.933 -0.758 -5.102 <0.0001 0.0028
BMI AUC0–2 Imitrex, 4 mg 76.802 -0.909 -8.232 0.0066 0.0162
BMI AUC0–2 Imitrex, 6 mg 114.530 -1.399 -8.708 0.0002 0.0234
BMI AUC
0–∞
 DFN-11, 3 mg 84.843
-0.924 -5.690 <0.0001 0.0091
BMI AUC
0–∞
Imitrex, 4 mg 107.650
-1.231 -12.333 0.0107 0.0134
BMI AUC
0–∞
Imitrex, 6 mg 154.500
-1.648 -10.478 0.0008 0.0360
Note: aExposure was lower in non-whites compared with whites (ratio of median values was 0.84 and 0.89, respectively). bStatistical significance (ANOVA) for inclusion of 
this term in the model.
Abbreviations: AUC, area under the curve; BMI, body mass index; Cmax, maximum plasma concentration.
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head-to-head comparison of DFN-11 to the two autoinjector 
products, Imitrex STATdose 4 mg and Imitrex STATdose 
6 mg. In that study, the incidence of injection site pain with 
DFN-11 was 39%, lower than that observed with Imitrex 
STATdose 6 mg (53%) and similar to Imitrex STATdose 
4 mg (42%). The incidence of injection site erythema with 
DFN-11 was 28%, higher than with Imitrex STATdose 6 mg 
(19%) and similar to Imitrex STATdose 4 mg (25%). All these 
events were mild in nature and resolved without medical 
intervention. The percentage of subjects experiencing at least 
one adverse event was 56% for DFN-11, 72% for Imitrex 
STATdose 4 mg, and 67% for Imitrex STATdose 6 mg.
Discussion
These post hoc exploratory analyses demonstrate a statisti-
cally significant impact of body size, assessed by weight and 
BMI, on systemic exposure to sumatriptan administered as 
DFN-11 or Imitrex. For each treatment group, subjects with 
lower BMI or weight had higher systemic exposure compared 
with subjects with higher BMI or weight. For both products, 
exposure was higher in women than in men, with ratios as 
high as 1.29; this sex effect is largely a function of weight 
(women weighing less than men).
In addition to evaluating C
max
 and AUC
0–∞
 as exposure 
metrics, we evaluated AUC
0–2
. This metric was selected (and 
prespecified in the analysis plan) because sumatriptan’s effi-
cacy window is typically within the first 2 hours; therefore, 
systemic exposure during this period is more relevant than 
systemic exposure well after efficacy is expected to wane.
For continuous covariates, the median value of the 
covariate was used to divide subjects into two groups; the 
median value for each metric was then compared between 
these groups. If the ratio were markedly less than unity, it 
would suggest that subjects weighing more or having a larger 
BMI experienced lower exposure for that metric. In turn, it 
might imply different dosing requirements as a function of 
that covariate.
These post hoc analyses demonstrate that sumatriptan 
exposure was higher in lighter subjects and those with BMI 
less than or equal to the median value. Several studies have 
reported that body size affects migraine response. Saracco et al6 
pooled ITT data from 346 subjects in three double-blind, 
placebo-controlled randomized studies with frovatriptan 
and other triptans. Pain-free rates at 2 hours were lower in 
obese subjects (27%) compared with nonobese subjects 
(34%). Visser et al7 mailed a survey questionnaire to 869 
migraine patients, of whom 735 (85%) replied. To deter-
mine risk factors for nonresponders to sumatriptan, the 
investigators compared clinical characteristics, demograph-
ics, and migraine-associated symptoms: non responders to 
SC sumatriptan had a higher BMI. In a post hoc analysis 
from a double-blind randomized, placebo-controlled 
study with rizatriptan 10 mg oral tablets in children aged 
12–17 years, weight <40 kg was associated with higher 
pain-free rates (34.6%) compared with weight ≥40 kg 
(30.2%).8 One of the limitations of this study was that the 
sample size for the <40 kg group was much smaller than 
that for the ≥40 kg group (26 vs 258). In contrast, the post 
hoc analysis of a combination product (sumatriptan 85 mg/
aproxen 500 mg) by Winner et al9 found no correlation 
between BMI and treatment response. Cosson and Fuseau10 
demonstrated a relationship between apparent clearance 
and weight and, consequently, an inverse relationship 
between AUC and weight. However, these investigators did 
not report the coefficient of that  relationship so we were 
unable to compare their results with ours.
Two prospective efficacy studies have compared sumatrip-
tan SC 3–6 mg. In a pilot study of SC sumatriptan, Landy et 
al11 reported that subjects preferred 3 mg over 6 mg: 66.7% 
of subjects administered 3 mg achieved a combined end point 
at 2 hours of being pain-free with no significant side effects 
compared with 50% of subjects administered with 6 mg. The 
difference between groups was larger at 24 hours: 63.3% vs 
33.3%. Preference for the smaller dose in both studies sug-
gests that larger doses, despite their potential for improved 
efficacy, may cause adverse effects limiting their utility.
Mathew et al12 reported similar 1-hour pain relief rates 
with 3 mg (57%) and 4 mg (50%) and a higher rate with 
Table 5 Effect of BMI on systemic exposure to sumatriptan.
Exposure metric DFN-11 3 mg Imitrex‚*
3 mg injection 4 mg STATdose 6 mg STATdose or injection
AUC0–2 (ng/mL h) 43.35/40.03
a 39.20/37.99a 52.51/48.61a 80.14/71.38a
AUC
0–∞
 (ng/mL h) 62.41/54.76a 57.23/52.46 72.24/70.94a 112.22/103.22a
Cmax (ng/mL) 51.2/45.2
a 48.1/43.65a 59.45/57.90 90.50/78.40a
Note: Values are (median for subjects with BMI less than or equal to median value)/(median for subjects with BMI more than median value). aSubjects < median BMI differ 
(P<0.05) from those > median BMI by t-test. *Generic name: Sumatriptan.
Abbreviations: AUC, area under the curve; BMI, body mass index; Cmax, maximum plasma concentration.
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6 mg (73%). Although both studies demonstrate that SC 3 mg 
provides pain relief to a significant number of migraineurs, 
major limitations of both are that sample sizes were small 
(30 subjects per group) and efficacy data were not stratified 
by BMI. The same study also reported few of certain triptan-
related adverse events – flushing, nausea, tingling, warm/
hot sensation, numbness, and dizziness – with sumatriptan 
injection 3 mg compared with 6 mg. Prospective studies 
are required to understand if BMI impacts efficacy of low-
dose sumatriptan injection or other triptans for episodic 
migraineurs. In addition, smaller doses may be preferred 
by certain subgroups of patients if they provide comparable 
efficacy with fewer adverse effects.
Conclusion
Weight and BMI appear to be important covariates for sumat-
riptan exposure: subjects with lower values for either metric 
of body size have higher systemic exposure compared with 
subjects with higher values. Additional studies are required to 
determine if doses of SC sumatriptan may be adjusted based 
on BMI for comparable efficacy and a potentially improved 
tolerability profile.
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